Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 12, 2025, reports a material definitive agreement entered into by Cadrenal Therapeutics, Inc. (the "Company"). The Company, an emerging growth company incorporated in Delaware, consummated an Asset Purchase Agreement on September 12, 2025, with eXIthera Pharmaceuticals, Inc. ("Seller").
Key Financial Metrics and Transaction Terms
The filing details the acquisition of assets related to the compounds Frunexian (EP-7041) and EP-7327, including intellectual property, regulatory filings, clinical data, and inventory. The purchase price structure is as follows:
- Upfront Cash Payment: $50,000 for transaction closing costs.
- Contingent Milestone Payments: Up to $15,000,000 total, payable in cash, common stock, or a combination thereof upon specific clinical and regulatory events.
- Royalty Obligations:
- 2% of Annual Net Sales for products containing the Compounds in countries outside China (subject to patent expiration, regulatory exclusivity, or a 10-year cap).
- 50% of all royalties received from the existing Haisco License Agreement regarding Frunexian in China.
Material Changes and Milestone Schedule
The transaction represents a significant expansion of the Company's anticoagulation pipeline. The contingent milestone payments are triggered by the following events:
- $500,000 upon first patient dosed in a Phase 2 study for Frunexian or an Other IV Compound.
- $500,000 upon first patient dosed in a Phase 1 study for EP-7327 or an Other Oral Compound.
- $1,000,000 upon first patient dosed in a Phase 3 study for Frunexian or an Other IV Compound.
- $1,000,000 upon first patient dosed in a Phase 3 study for EP-7327 or an Other Oral Compound.
- $6,000,000 upon FDA approval of an NDA for Frunexian or an Other IV Compound.
- $6,000,000 upon FDA approval of an NDA for EP-7327 or an Other Oral Compound.
The filing does not provide specific revenue, profit, cash flow, or debt figures for the Company as this is a current report regarding a specific event rather than a periodic financial statement.
Guidance, Risks, and Management Commentary
The Company issued a press release on September 15, 2025, announcing the acquisition. Management included forward-looking statements regarding the development of Frunexian and the payment of milestones. These statements are subject to risks and uncertainties, including the failure to achieve clinical milestones or regulatory approvals. The Company assumes post-closing obligations under the Haisco License Agreement only to the extent they do not arise from prior breaches by the Seller.
Investor Verification Checklist
- Verify the Company's current cash position to assess the ability to fund the $50,000 upfront payment and future milestone obligations.
- Review the full Asset Purchase Agreement (Exhibit 10.1) for detailed definitions of "Annual Net Sales" and "Other IV/Oral Compounds."
- Confirm the status of the Haisco License Agreement and the potential volume of royalties to be shared with the Seller.
- Monitor upcoming clinical trial announcements for Frunexian and EP-7327 to track progress toward the $15 million in potential milestones.
- Assess the impact of the 2% royalty on future gross margins for any commercialized products outside of China.